On behalf of Vision Expo, we sincerely thank you for being with us this year.

Vision Expo Has Gone Green!

We have eliminated all paper session evaluation forms. Please be sure to complete your electronic session evaluations online when you login to request your C2 letter for each course you attended! Your feedback is important to us as our Education Planning Committee considers content and speakers for future meetings to provide you with the best education possible.

1

2



Financial Disclosure – Justin Schweitzer, OD, FAAO 181-0/

Sight Sciences – C/L	
Dompe – C	
Zeiss – C/L	
visus - C	
cience Based Health – C	
Kala – C	
RVL-C	


- 4


Case

 $^{\prime\prime}l$ have noticed a steady decline in my vision and glasses don't seem to fix it. I am also noticing some fluctuation in my vision"


- 29-year-old female w/reduced vision
- Refraction: OD: -0.75–2.25 x 34 20/15 OS: -1.75--0.75 x 15 20/15
- Ocular Allergies w/ eye-rubbing
- SLEx: Remarkable for conjunctival injection, otherwise unremarkable.

5
















. Olivanes JI, Guerrero JC, Bermudez FR. Kerstoconuc: age of onset and natural history. Optom Vis Sci 1997;7: Yye Bask Association of America Statistical Report, 2014




10









2/20/24










- Preserve spectacle corrected visual acuity
- Stabilize (cross link) prior to anterior corneal changes
- Delay/eliminate need for corneal transplantation
- Identify patients at risk of ectasia after corneal refractive surgery

Frender				









When to Consider Tomography

- Increasing astigmatism
- Central K value > 47.2 page
- Astigmatism >2.0 D (~8% of the population)
- Unable to correct to 20/15 to 20/20
- Asymmetry between eyes
- Scissoring with retinoscope



22


Genetic Testing for at Risk Patients

- Non-invasive cheek swab test
- Examines over 1,000 variants across 75 genes for keratoconus
 0 to 100 green-yellow-red scale based on research done by Avellino and study populations























Use in Specific Populations: Label

No contraindications


Safety and effectiveness not established in pediatric patients below the age of 14 or over the age of 65

Cross-linking should not be performed on pregnant women.











Post-operative course: What's normal?

- Day 1-5:


- Day 1-5: Discomfort as epithelium heals (BCL in place) Sensitivity to light Tearing A reduction and fluctuation in vision


38










































Corneal Tissue Addition Keratoplasty (CTAK)

- Developed at Cornea and Laser Eye Institute
 O Peter Hersh MD, Steven Greenstein MD, John Gel
- Sterilized gamma irradiated tissue
- Customized to individual by tomography
- Femtosecond customizable shapes
- Implanted through femtosecond corneal chann




€≊ 55























Additional/Future Applications



63

Epi-On Corneal Cross-Linking

Iontophoresis or penetration enhancers Epithelium absorbs 20% of incoming UV and barrier to O2



Increase UV fluence results in reduction of O2 Pulse CXL O2 Goggles Getting Close!! Penetration Enhancers Optimized UV irradiation profiles Atmospheric O2

66

US FDA Phase III Oxygen + Transepithelial CXL


Riboflavin formulations

- Penetrate intact epi
- UV Delivery
 - Accelerated and Pulsed
 - ~1/3 procedure time
- Oxygen supplement
- Aerobic cornea



Oxygen + Transepi CXL

- Oxygen depleted in traditional CXL
- Oxygen supplementation:
 - Significantly greater stiffening (p < .05) than epi-on tissue crosslinked without additional oxygen
 - No statistical difference between the epi-on protocol oxygen and epi-off Dresden protocol (p ≥ 0.05)
 - No statistical difference between the negative of epi-on treatment without oxygen (p ≥ 0.05)
 - The oxygen protocol produced more central flattening than the other epi-on protocols (p < .05)



68

US Phase III Pivotal Trial Results

- Achieved primary efficacy outcome
- -1.0 D difference in Kmax at 6 months (p=0.0004).
- Well-tolerated
- 98% of placebo eyes elected to cross-over for Epi-on treatment



69

What is going to happen next

Predicting the Future is Easy......

.....Being Right is Hard

-Yogi Berra

